Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

4,974 studies for “Parkinson disease”

Characterization and Validation of the Short Physical Performance Battery in Individuals Diagnosed With Parkinson's DiseaseRecruiting
NCT07780461N/AUpdated Aug 21, 2026
Sponsor: University of Vigo
PARKINSON DISEASE (Disorder)
Spain
Combined Genome and RNA Sequencing for Genetic Diagnosis of ParkinsonismRecruiting
NCT06576713NAUpdated Aug 21, 2026
Sponsor: University Hospital, Strasbourg, France
Parkinson's Disease
France
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).Terminated
NCT04949256Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Metastatic Esophageal Squamous Cell Carcinoma
United States, Argentina, Canada, Chile, China +20 more
GBPDC: Gut-Brain in PD Consortium Master ProtocolRecruiting
NCT07567794N/AUpdated Aug 21, 2026
Sponsor: Duke University
Parkinson Disease (PD) · PARKINSON DISEASE (Disorder) · Gut Microbiome · Gut Microbiota
United States
A Novel Digital Music-based Autonomous Personalized Walking Intervention to Improve Gait and Walking Automaticity in Parkinson DiseaseRecruiting
NCT07705373NAUpdated Aug 21, 2026
Sponsor: Boston University Charles River Campus
Parkinson's Disease (PD)
United States
STN-tTIS With Different Intervention Intervals Versus Standard Medical Treatment for Parkinson's DiseaseRecruiting
NCT07774312NAUpdated Aug 21, 2026
Sponsor: Ruijin Hospital
Parkinson's Disease (PD)
China
Genetics and Aerobic Exercise to Slow Parkinson's Disease TrialRecruiting
NCT06442033NAUpdated Aug 21, 2026
Sponsor: Jay Alberts
Parkinson Disease
United States
Cross-System Effects of Acute Intermittent Hypercapnia-Based Interventions in PDRecruiting
NCT07674264NAUpdated Aug 21, 2026
Sponsor: University of Florida
Parkinson Disease · Parkinsonism
United States
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)Recruiting
NCT06841354Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
United States, Argentina, Australia, Belgium, Brazil +29 more
Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System AtrophyCompleted
NCT06671938Phase 2Updated Aug 21, 2026
Sponsor: BioArctic AB
Parkinson Disease · Multiple System Atrophy
Poland, Spain
A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease.Recruiting
NCT06466525Phase 1Updated Aug 21, 2026
Sponsor: Longevity Biotech Australia Pty Ltd (subsidiary)
Parkinson Disease
Australia
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)Recruiting
NCT06623422Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
United States, Argentina, Australia, Belgium, Brazil +26 more
Deep Brain Stimulation Therapy in Movement DisordersRecruiting
NCT02119611NAUpdated Aug 21, 2026
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Parkinson's Disease
United States
An Unblinded, Single Arm, Pilot Observational Study to Test the Safety, Tolerability, Immunogenicity and the Biological Effects of TRB-001 Vaccination in Individuals Who Have Previously Undergone aSyn ImmunotherapyRecruiting
NCT07777484Phase 1Updated Aug 20, 2026
Sponsor: Tridem Bioscience FlexCo
Parkinson's Disease
Austria
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension StudyActive Not Recruiting
NCT05899049Phase 3Updated Aug 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
China
Adaptive Neurostimulation to Restore Sleep in Parkinson's DiseaseCompleted
NCT04620551NAUpdated Aug 20, 2026
Sponsor: University of Nebraska
Parkinson Disease · Sleep Fragmentation
United States
Hereditary Parkinson s Disease Natural History ProtocolCompleted
NCT02511015N/AUpdated Aug 20, 2026
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Parkinson Disease 6, Early-Onset · Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human · Parkinson Disease Autosomal Recessive, Early Onset · Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1
United States
Telehealth in Lewy Body DementiaActive Not Recruiting
NCT05014971NAUpdated Aug 20, 2026
Sponsor: University of Florida
Lewy Body Dementia With Behavioral Disturbance · Lewy Body Parkinson Disease · Lewy Body Disease
United States
Personalized Real-Time DBS and PD MechanismsRecruiting
NCT06013956Phase 4Updated Aug 20, 2026
Sponsor: David Escobar
Parkinson Disease
United States
Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCCNot Yet Recruiting
NCT07776340Phase 2Updated Aug 20, 2026
Sponsor: Fudan University
HPV-unrelated Head and Neck Squamous Cell Carcinoma
China
French Parkinson's Disease Cohort - NS-PARKRecruiting
NCT04888364N/AUpdated Aug 20, 2026
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Parkinson Disease
France
Impact of Subthalamic Nucleus Deep Brain Stimulation on COGnitive and PSYchiatric Symptoms in Parkinson's DiseaseNot Yet Recruiting
NCT07777419NAUpdated Aug 20, 2026
Sponsor: Insel Gruppe AG, University Hospital Bern
Parkinsons Disease (PD)
Switzerland
Research Into the Expression of the csgA-gene and How it Changes in Patients With Parkinson's DiseaseRecruiting
NCT07175922N/AUpdated Aug 19, 2026
Sponsor: Vertero Therapeutics
Parkinsons Disease (PD)
Netherlands
Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients.Withdrawn
NCT05931484Phase 2Updated Aug 19, 2026
Sponsor: Forest Hills Lab
Parkinson Disease
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)Completed
NCT03740165Phase 3Updated Aug 19, 2026
Sponsor: Merck Sharp & Dohme LLC
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms
United States, Australia, Belgium, Brazil, Canada +17 more

4,974 studies found